The impact of the genetic background in the Noonan syndrome phenotype induced by K-Ras^V14I

References

• Rauen KA. The RASopathies. Annu Rev Genomics Hum Genet 2013; 14:355-69; PMID:23875798; http://dx.doi.org/10.1146/annurev-genom-091212-153523.
   PubMed Web of Science ®Google Scholar
• Roberts AE, Allanson JE, Tartaglia M, Gelb BD. Noonan syndrome. Lancet 2013; 381:333-42; PMID:23312968; http://dx.doi.org/10.1016/S0140-6736(12)61023-X
   PubMed Web of Science ®Google Scholar
• Aoki Y, Niihori T, Banjo T, Okamoto N, Mizuno S, Kurosawa K, Otaga T, Takada F, Yano M, Ando T, et al. Gain-of-function mutations in RIT1 cause Noonan syndrome, a RAS/MAPK pathway syndrome. Am J Hum Genet 2013; 93:173-80; PMID:23791108; http://dx.doi.org/10.1016/j.ajhg.2013.05.021
   PubMed Web of Science ®Google Scholar
• Flex E, Jaiswal M, Pantaleoni F, Martinelli S, Strullu M, Fansa EK, Caye A, De Luca A, Lepri F, Dvorsky R, et al. Activating mutations in RRAS underlie a phenotype within the RASopathy spectrum and contribute to leukaemogenesis. Hum Mol Genet 2014; 23:4315-27; PMID:24705357; http://dx.doi.org/10.1093/hmg/ddu148
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Gelb BD, Zenker M. Noonan syndrome and clinically related disorders. Best Pract Res Clin Endocrinol Metab 2011; 25:161-79; PMID:21396583; http://dx.doi.org/10.1016/j.beem.2010.09.002
   PubMed Web of Science ®Google Scholar
• Schubbert S, Shannon K, Bollag G. Hyperactive Ras in developmental disorders and cancer. Nat Rev Cancer 2007; 7:295-308; PMID:17384584; http://dx.doi.org/10.1038/nrc2109
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Kalidas K, Shaw A, Song X, Musat DL, van der Burgt I, Brunner HG, Bertola DR, Crosby A, Ion A, et al. PTPN11 mutations in Noonan syndrome: molecular spectrum, genotype-phenotype correlation, and phenotypic heterogeneity. Am J Hum Genet 2002; 70:1555-63; PMID:11992261; http://dx.doi.org/10.1086/340847
   PubMed Web of Science ®Google Scholar
• Zenker M, Horn D, Wieczorek D, Allanson J, Pauli S, van der Burgt I, Doerr HG, Gaspar H, Hofbeck M, Gillessen-Kaesbach G, et al. SOS1 is the second most common Noonan gene but plays no major role in cardio-facio-cutaneous syndrome. J Med Genet 2007; 44:651-6; PMID:17586837; http://dx.doi.org/10.1136/jmg.2007.051276
   PubMed Web of Science ®Google Scholar
• Tartaglia M, Gelb BD. Disorders of dysregulated signal traffic through the RAS-MAPK pathway: phenotypic spectrum and molecular mechanisms. Ann N Y Acad Sci 2010; 1214:99-121; PMID:20958325; http://dx.doi.org/10.1111/j.1749-6632.2010.05790.x
   PubMed Web of Science ®Google Scholar
• Sarkozy A, Carta C, Moretti S, Zampino G, Digilio MC, Pantaleoni F, Scioletti AP, Esposito G, Cordeddu V, Lepri F, et al. Germline BRAF mutations in Noonan, LEOPARD, and cardiofaciocutaneous syndromes: molecular diversity and associated phenotypic spectrum. Hum Mutat 2009; 30:695-702; PMID:19206169; http://dx.doi.org/10.1002/humu.20955
   PubMed Web of Science ®Google Scholar
• Lee BH, Kim JM, Jin HY, Kim GH, Choi JH, Yoo HW. Spectrum of mutations in Noonan syndrome and their correlation with phenotypes. J Pediatr 2011; 159:1029-35; PMID:21784453; http://dx.doi.org/10.1016/j.jpeds.2011.05.024
   PubMed Web of Science ®Google Scholar
• Bertola DR, Pereira AC, de Oliveira PS, Kim CA, Krieger JE. Clinical variability in a Noonan syndrome family with a new PTPN11 gene mutation. Am J Med Genet A 2004; 130A:378-83; PMID:15384080; http://dx.doi.org/10.1002/ajmg.a.30270
   PubMed Web of Science ®Google Scholar
• Zenker M, Voss E, Reis A. Mild variable Noonan syndrome in a family with a novel PTPN11 mutation. Eur J Med Genet 2007; 50:43-7; PMID:17052965; http://dx.doi.org/10.1016/j.ejmg.2006.08.003
   PubMed Web of Science ®Google Scholar
• Bentires-Alj M, Kontaridis MI, Neel BG. Stops along the RAS pathway in human genetic disease. Nat Med 2006; 12:283-5; PMID:16520774; http://dx.doi.org/10.1038/nm0306-283
   PubMed Web of Science ®Google Scholar
• Araki T, Chan G, Newbigging S, Morikawa L, Bronson RT, Neel BG. Noonan syndrome cardiac defects are caused by PTPN11 acting in endocardium to enhance endocardial-mesenchymal transformation. Proc Natl Acad Sci U S A 2009; 106:4736-41; PMID:19251646; http://dx.doi.org/10.1073/pnas.0810053106
   PubMed Web of Science ®Google Scholar
• Wu X, Simpson J, Hong JH, Kim KH, Thavarajah NK, Backx PH, Neel BG, Araki T. MEK-ERK pathway modulation ameliorates disease phenotypes in a mouse model of Noonan syndrome associated with the Raf1(L613V) mutation. J Clin Invest 2011; 121:1009-25; PMID:21339642; http://dx.doi.org/10.1172/JCI44929
   PubMed Web of Science ®Google Scholar
• Wu X, Yin J, Simpson J, Kim KH, Gu S, Hong JH, Bayliss P, Backx PH, Neel BG, Araki T. Increased BRAF heterodimerization is the common pathogenic mechanism for noonan syndrome-associated RAF1 mutants. Mol Cell Biol 2012; 32: 3872-90; PMID:22826437; http://dx.doi.org/10.1128/MCB.00751-12
   PubMed Web of Science ®Google Scholar
• Pritchard CA, Bolin L, Slattery R, Murray R, McMahon M. Post-natal lethality and neurological and gastrointestinal defects in mice with targeted disruption of the A-Raf protein kinase gene Curr Biol 1996; 6: 614-7; PMID:8805280; http://dx.doi.org/10.1016/S0960-9822(02)00548-1
   PubMed Web of Science ®Google Scholar
• Hernandez-Porras I, Fabbiano S, Schuhmacher AJ, Aicher A, Canamero M, Camara JA, Cusso L, Desco M, Heeschen C, Mulero F, et al. K-RasV14I recapitulates Noonan syndrome in mice Proc Natl Acad Sci U S A 2014; 111:16395-16400; PMID:25359213; http://dx.doi.org/10.1073/pnas.1418126111
   PubMed Web of Science ®Google Scholar
• Chen PC, Wakimoto H, Conner D, Araki T, Yuan T, Roberts A, Seidman CE, Bronson R, Neel BG, Seidman JG et al. Activation of multiple signaling pathways causes developmental defects in mice with a Noonan syndrome-associated Sos1 mutation. J Clin Invest 2010; 120: 4353-65; PMID:21041952; http://dx.doi.org/10.1172/JCI43910
   PubMed Web of Science ®Google Scholar
• Tidyman WE, Rauen KA. Noonan, Costello and cardio-facio-cutaneous syndromes: dysregulation of the Ras-MAPK pathway. Expert Rev Mol Med 2008; 10:e37; PMID:19063751; http://dx.doi.org/10.1017/S1462399408000902
   PubMedGoogle Scholar
• Friedman JM, Gutmann DH, MacCollin M, Riccardi VM. Neurofibromatosis: phenotype, natural history, and pathogenesis. Taylor & Francis, Baltimore 1999.
   Google Scholar
• Easton DF, Ponder MA, Huson SM, Ponder BA. An analysis of variation in expression of neurofibromatosis (NF) type 1 (NF1): evidence for modifying genes. Am J Hum Genet 1993; 53:305-13; PMID:8328449
   PubMed Web of Science ®Google Scholar
• Szudek J, Joe H, Friedman JM. Analysis of intrafamilial phenotypic variation in neurofibromatosis 1 (NF1). Genet Epidemiol 2002; 23:150-64; PMID:12214308; http://dx.doi.org/10.1002/gepi.1129
   PubMed Web of Science ®Google Scholar
• Sabbagh A, Pasmant E, Laurendeau I, Parfait B, Barbarot S, Guillot B, Combemale P, Ferkal S, Vidaud M, Aubourg P, et al. Unravelling the genetic basis of variable clinical expression in neurofibromatosis 1. Hum Mol Genet 2009; 18:2768-78; PMID:19417008; http://dx.doi.org/10.1093/hmg/ddp212
   PubMed Web of Science ®Google Scholar
• Pemov A, Sung H, Hyland PL, Sloan JL, Ruppert SL, Baldwin AM, Boland JF, Bass SE, Lee HJ, Jones KM, et al. Genetic Modifiers of Neurofibromatosis Type 1-Associated Cafe-au-Lait Macule Count Identified Using Multi-platform Analysis. PLoS Genet 2014; 10:e1004575; PMID:25329635; http://dx.doi.org/10.1371/journal.pgen.1004575
   PubMed Web of Science ®Google Scholar
• Reilly KM, Broman KW, Bronson RT, Tsang S, Loisel DA, Christy ES, Sun Z, Diehl J, Munroe DJ, Tuskan RG. An imprinted locus epistatically influences Nstr1 and Nstr2 to control resistance to nerve sheath tumors in a neurofibromatosis type 1 mouse model. Cancer Res 2006; 66:62-8; PMID:16397217; http://dx.doi.org/10.1158/0008-5472.CAN-05-1480
   PubMed Web of Science ®Google Scholar
• Walrath JC, Fox K, Truffer E, Gregory Alvord W, Quinones OA, Reilly KM. Chr 19(A/J) modifies tumor resistance in a sex- and parent-of-origin-specific manner. Mamm Genome 2009; 20:214-23; PMID:19347398; http://dx.doi.org/10.1007/s00335-009-9179-4
   PubMed Web of Science ®Google Scholar
• Lin AE, Alexander ME, Colan SD, Kerr B, Rauen KA, Noonan J, Baffa J, Hopkins E, Sol-Church K, Limongelli G, et al. Clinical, pathological, and molecular analyses of cardiovascular abnormalities in Costello syndrome: a Ras/MAPK pathway syndrome. Am J Med Genet A 2011; 155A:486-507; PMID:21344638; http://dx.doi.org/10.1002/ajmg.a.33857
   PubMed Web of Science ®Google Scholar
• Baldassarre G, Mussa A, Banaudi E, Rossi C, Tartaglia M, Silengo M, Ferrero GB. Phenotypic variability associated with the invariant SHOC2 c.4A>G (p.Ser2Gly) missense mutation. Am J Med Genet A 2014; 164A:3120-5; PMID:25331583; http://dx.doi.org/10.1002/ajmg.a.36697
   PubMed Web of Science ®Google Scholar
• Jongmans M, Sistermans EA, Rikken A, Nillesen WM, Tamminga R, Patton M, Maier EM, Tartaglia M, Noordam K, van der Burgt I. Genotypic and phenotypic characterization of Noonan syndrome: new data and review of the literature. Am J Med Genet A 2005; 134A:165-70; PMID:15723289; http://dx.doi.org/10.1002/ajmg.a.30598
   PubMed Web of Science ®Google Scholar
• Musante L, Kehl HG, Majewski F, Meinecke P, Schweiger S, Gillessen-Kaesbach G, Wieczorek D, Hinkel GK, Tinschert S, Hoeltzenbein M, et al. Spectrum of mutations in PTPN11 and genotype-phenotype correlation in 96 patients with Noonan syndrome and five patients with cardio-facio-cutaneous syndrome. Eur J Hum Genet 2003; 11:201-6; PMID:12634870; http://dx.doi.org/10.1038/sj.ejhg.5200935
   PubMed Web of Science ®Google Scholar
• Zenker M, Buheitel G, Rauch R, Koenig R, Bosse K, Kress W, Tietze HU, Doerr HG, Hofbeck M, Singer H, et al. Genotype-phenotype correlations in Noonan syndrome. J Pediatr 2004; 144:368-74; PMID:15001945; http://dx.doi.org/10.1016/j.jpeds.2003.11.032
   PubMed Web of Science ®Google Scholar
• Ezquieta B, Santome JL, Carcavilla A, Guillen-Navarro E, Perez-Aytes A, Sanchez del Pozo J, Garcia-Miñuar S, Castillo E, Alonso M, Vendrell T, et al. Alterations in RAS-MAPK genes in 200 Spanish patients with Noonan and other neuro-cardio-facio-cutaneous syndromes. Genotype and cardiopathy. Rev Esp Cardiol (Engl Ed) 2012; 65:447-55; PMID:22465605; http://dx.doi.org/10.1016/j.recesp.2011.12.016
   PubMed Web of Science ®Google Scholar
• Simpson EM, Linder CC, Sargent EE, Davisson MT, Mobraaten LE, Sharp JJ. Genetic variation among 129 substrains and its importance for targeted mutagenesis in mice. Nat Genet 1997; 16:19-27; PMID:9140391; http://dx.doi.org/10.1038/ng0597-19
   PubMed Web of Science ®Google Scholar
• Chen X, Mitsutake N, LaPerle K, Akeno N, Zanzonico P, Longo VA, Mitsutake S, Kimura ET, Geiger H, Santos E, et al. Endogenous expression of Hras(G12V) induces developmental defects and neoplasms with copy number imbalances of the oncogene. Proc Natl Acad Sci U S A 2009; 106:7979-84; PMID:19416908; http://dx.doi.org/10.1073/pnas.0900343106
   PubMed Web of Science ®Google Scholar
• Schuhmacher AJ, Guerra C, Sauzeau V, Canamero M, Bustelo XR, Barbacid M. A mouse model for Costello syndrome reveals an Ang II-mediated hypertensive condition. J Clin Invest 2008; 118:2169-79; PMID:18483625
   PubMed Web of Science ®Google Scholar
• Urosevic J, Sauzeau V, Soto-Montenegro ML, Reig S, Desco M, Wright EM, Cañamero M, Mulero F, Ortega S, Bustelo XR, et al. Constitutive activation of B-Raf in the mouse germline provides a model for human cardio-facio-cutaneous syndrome. Proc Natl Acad Sci U S A 2011; 108:5015-20; PMID:21383153; http://dx.doi.org/10.1073/pnas.1016933108
   PubMed Web of Science ®Google Scholar